In the present study, we found that KIF2A expression was elevated in AML patients compared to healthy controls, which was in line with the data on AML patient datasets from GEO database, and KIF2A had a good diagnostic value for AML risk. This evidence concerns the gene KIF2A and acute myeloid leukemia.